Head-to-head comparisons of medication uses, side effects, warnings, and more.
Key takeaways
Tremfya (guselkumab) and Otezla (apremilast) are both medications used to treat plaque psoriasis and active psoriatic arthritis. However, they belong to different medication classes and have distinct characteristics. Tremfya is a monoclonal antibody that is administered as an injection under the skin, while Otezla is a phosphodiesterase-4 (PDE-4) inhibitor taken orally. Tremfya is additionally approved for moderate-to-severe ulcerative colitis and Crohn's disease, whereas Otezla is also approved for treating mouth sores from Behçet’s disease. Tremfya is typically injected every 8 weeks after initial doses, while Otezla is taken orally and requires a gradual increase in dosage over the first 5 days, eventually reaching a maintenance dose taken twice daily. Tremfya is only available as a brand-name medication, making it potentially more expensive, whereas generic versions of Otezla are available. Common side effects of Tremfya include upper respiratory infections and injection site reactions, while Otezla often causes nausea and diarrhea.
Tremfya (guselkumab)
Otezla (apremilast)
Tremfya (guselkumab)
Otezla (apremilast)
Summary of Tremfya vs. Otezla
Summary for Interleukin antagonist
Prescription only
Tremfya (guselkumab) is an injection used to treat certain inflammatory conditions. It's for people ages 6 year and older with plaque psoriasis or psoriatic arthritis. It can also treat adults with ulcerative colitis (UC) or Crohn's disease. This medication is an interleukin antagonist that works to lower inflammation. The dosing schedule is usually every 2 months after the starter doses. Adults with UC or Crohn's disease can also get their maintenance doses once a month. Side effects are upper respiratory infections, headache, and injection site reactions. Long-term side effects include a risk of other infections and liver problems.
Summary for PDE-4 inhibitor
Prescription only
Otezla (apremilast) is a tablet that's taken by mouth. It treats plaque psoriasis and psoriatic arthritis in people 6 years and older. The medication can also treat mouth sores from Behçet’s disease in adults. It works as a phosphodiesterase-4 (PDE4) inhibitor to reduce inflammation. Immediate-release tablets called Otezla are taken twice daily. You start at a low dose, then it gets raised over a few days to a maintenance dose. Some people can switch to once-daily, extended-release tablets called Otezla XR. Side effects include nausea and diarrhea.
Indications of Tremfya vs. Otezla
Indications for
•Moderate-to-severe plaque psoriasis - adults and children 6 years and older